Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

Bob Lowenberg*, Joachim Beck, Carlos Graux, Wim van Putten, Harry C. Schouten, Leo F. Verdonck, Augustin Ferrant, Pieter Sonneveld, Mojca Jongen-Lavrencic, Marie von Lilienfeld-Toal, Bart J. Biemond, Edo Vellenga, Dimitri Breems, Hilde de Muijnck, M Ron Schaafsma, Gregor E. G. Verhoef, Hartmut Doehner, Alois Gratwohl, Thomas Pabst, Gert Jan OssenkoppeleJohan Maertens

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)2586-2591
Issue number13
Publication statusPublished - 1 Apr 2010

Cite this